(Q42553192)

2 November 2017

title

Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients (English)

1 reference

2 November 2017

1 reference

1 reference

1 reference

1

Pierre J. Blanchet

1 reference

2 November 2017

2

Paul Allard

1 reference

2 November 2017

3

Laurent Grégoire

1 reference

2 November 2017

4

François Tardif

1 reference

2 November 2017

5

Paul J. Bédard

1 reference

2 November 2017

publication date

1 August 1996

1 reference

Canadian Journal of Neurological Sciences

2 November 2017

published in

1 reference

2 November 2017

volume

23

1 reference

2 November 2017

issue

3

1 reference

2 November 2017

page(s)

189-193

1 reference

When to use levodopa in parkinsonism.

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Effect of age at onset on progression and mortality in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Levodopa-induced dyskinesia: review, observations, and speculations

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

The prevalence and aetiology of long-term L-dopa side-effects in elderly parkinsonian patients

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Aromatic Amino Acids and Modification of Parkinsonism

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

L-dopa long-term treatment in Parkinson's disease: age-related side effects.

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Levodopa-induced dyskinesia: clinical observations

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Young onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

Does levodopa aggravate Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1017%2FS031716710003849X

7 January 2021

10.1017/S031716710003849X

Identifiers

DOI

0 references

1 reference